Skip to main content

Published locations for Relapsing MS: Ofatumumab demonstrates superior benefit-risk profile than teriflunomide in RDTN patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Relapsing MS: Ofatumumab demonstrates superior benefit-risk profile than teriflunomide in RDTN patients

User login

  • Reset your password
  • /content/relapsing-ms-ofatumumab-demonstrates-superior-benefit-risk-profile-teriflunomide-rdtn
  • /neurology/msresourcecenter/article/254122/multiple-sclerosis/relapsing-ms-ofatumumab-demonstrates